These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 28103785)

  • 1. Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease.
    Hoare SRJ; Grigoriadis DE
    Curr Mol Pharmacol; 2017; 10(4):282-295. PubMed ID: 28103785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
    Fahmy H; Kuppast B; Ismail MT
    Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticotropin-releasing factor 1 receptor antagonists: a patent review.
    Williams JP
    Expert Opin Ther Pat; 2013 Aug; 23(8):1057-68. PubMed ID: 23642023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonism.
    Spyridaki K; Matsoukas MT; Cordomi A; Gkountelias K; Papadokostaki M; Mavromoustakos T; Logothetis DE; Margioris AN; Pardo L; Liapakis G
    J Biol Chem; 2014 Jul; 289(27):18966-77. PubMed ID: 24838244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1.
    Bhattacharya S; Subramanian G; Hall S; Lin J; Laoui A; Vaidehi N
    J Comput Aided Mol Des; 2010 Aug; 24(8):659-74. PubMed ID: 20512399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development.
    Hurevich M; Talhami A; Shalev DE; Gilon C
    Curr Top Med Chem; 2014; 14(15):1842-63. PubMed ID: 25175995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of class B GPCR corticotropin-releasing factor receptor 1.
    Hollenstein K; Kean J; Bortolato A; Cheng RK; Doré AS; Jazayeri A; Cooke RM; Weir M; Marshall FH
    Nature; 2013 Jul; 499(7459):438-43. PubMed ID: 23863939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
    Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
    Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in corticotropin-releasing factor-1 antagonist development.
    Zorrilla EP; Koob GF
    Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.
    Hoyer D; Bartfai T
    Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures.
    Dore AS; Bortolato A; Hollenstein K; Cheng RKY; Read RJ; Marshall FH
    Curr Mol Pharmacol; 2017; 10(4):334-344. PubMed ID: 28183242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the binding site crevice of a family B G protein-coupled receptor, the type 1 corticotropin releasing factor receptor.
    Gkountelias K; Papadokostaki M; Javitch JA; Liapakis G
    Mol Pharmacol; 2010 Oct; 78(4):785-93. PubMed ID: 20664003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Approaches to GPCR Ligand Screening for Drug Discovery.
    Kumari P; Ghosh E; Shukla AK
    Trends Mol Med; 2015 Nov; 21(11):687-701. PubMed ID: 26481827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Corticotropin Releasing Factor Receptor (CRFR) Activation Using Structural Models.
    Cordomi A; Liapakis G; Matsoukas MT
    Curr Mol Pharmacol; 2017; 10(4):325-333. PubMed ID: 28103783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.
    Ramsey SJ; Attkins NJ; Fish R; van der Graaf PH
    Br J Pharmacol; 2011 Oct; 164(3):992-1007. PubMed ID: 21449919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.
    Liang YL; Belousoff MJ; Zhao P; Koole C; Fletcher MM; Truong TT; Julita V; Christopoulos G; Xu HE; Zhang Y; Khoshouei M; Christopoulos A; Danev R; Sexton PM; Wootten D
    Mol Cell; 2020 Feb; 77(3):656-668.e5. PubMed ID: 32004469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors.
    Perrin MH; Grace CR; Riek R; Vale WW
    Ann N Y Acad Sci; 2006 Jul; 1070():105-19. PubMed ID: 16888152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.